Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Early Phase 1

A Trial of RLX-2508-102 in Healthy Volunteers

NCT07873671 · tracked via the Priya Life Science Australia tracker
Phase
Early Phase 1
Started
2026-11-15
Last updated
2026-10-14

Condition(s) studied

Influenza

Investigational drug(s) / intervention(s)

RLX-2508RLX-2508RLX-2508RLX-2508

RLX-2508: Single dose RLX-2508 /placebo given subcutaneously - Dose level 1

RLX-2508: Single dose RLX-2508 /placebo given subcutaneously - Dose level 2

RLX-2508: Repeated dose of RLX-2508 /placebo given subcutaneously - Dose level 3

RLX-2508: Single dose of RLX-2508 /placebo given subcutaneously - Dose level 3

Study summary

The purpose of this study is to assess safety, PK and immunogenicity profile of a single dose and multiple dose of RLX-2508 in healthy participants across different ethnic backgrounds.

Eligibility

Sex
ALL
Min age
18 Years
Max age
64 Years
Healthy volunteers
Accepted
Main inclusion criteria 1. Male or female participant, including general adult populations, and participants of Japanese heritage. 2. Capable to give consent and have ability to understand the trial procedures and possible adverse events, volunteer to participate in the trial, and provide written informed consent, be able to comply with all the requirements, and able to complete the study. 3. Women with body weight ≥ 45.0 kg, men with body weight ≥ 50.0 kg, body mass index (BMI) between 19.0 and 32.0 kg/m2 (inclusive) at screening and baseline, except for Japanese participants, for whom a BMI range of 18.0 to 28.0 kg/m² (inclusive) will apply. 4. Men and WOCBP must agree to take highly effective contraceptive methods Main exclusion Criteria 1. History or evidence of clinically significant disorders. 2. Individuals with a history of drug allergies, specific allergies, or known history or suspected of being allergic to the study drug or same class drug or any component of it. 3. Previous participation in another clinical trial (including medical devices or another investigational drug) within 3 months or 5 half-lives, whichever is longer prior to screening. 4. History of excessive smoking in the past 1 month prior to screening 5. History of illicit or prescription drug abuse or addiction within 1 year of screening, or positive urine drug screen at baseline. 6. Any other circumstances (e.g., not suitable for venous access) or laboratory abnormality that, in the investigator's judgment, may increase the risk to the participant, or be associated with the participant's participation in and completion of the study or could preclude the evaluation of the participant's response. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

Primary outcome measure(s)

  • Safety and Tolerability Based on Incidence and Severity of Treatment Emergent Adverse Events — Day 360 & Day 450
    Number of participants with Adverse events and Serious adverse events

Trial sites (3)

FacilityCityRegionStatus
Nucleus Network Sydney Sydney New South Wales
Nucleus Network Brisbane Brisbane Queensland
Nucleus Network Melbourne Melbourne Victoria
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07873671 on ClinicalTrials.gov ↗ ← All trials in Australia